Clinical trials: Antipsychotics
Schizophrenia
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
The purpose of this study is to investigate the effects of flexibly dosed Brexpiprazole monotherapy in the improvement of early-episode schizophrenia through the assessment of social functioning, efficacy, and tolerability.
- Trial name
- NCT02013622
- Testing
- Brexpiprazole
- Where
- 22 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychosis
A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
Antipsychotic drugs are used to treat a range of psychiatric disorders including schizophrenia, bipolar disorders, and psychotic depression.
- Trial name
- MetaboMicrobe (NCT06729671)
- Testing
- Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsule, maltodextrin
- Where
- 2 sites in Ireland
- Volunteers
- 70 people
- Sponsor
- University College Cork
Autism
Aripiprazole in Children With Autism: A Pilot Study
This is a 6-week open pilot study of aripiprazole for the treatment of adolescents, aged 12 to 18 years, diagnosed with autism. Children who qualify for the study will be treated with aripiprazole for 6 weeks.
- Trial name
- NCT00208533
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Drexel University College of Medicine
Tobacco Dependence, Schizophrenia
The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia
Cigarette smoking represents a major health problem for patients suffering from schizophrenia. Compared to the general population, schizophrenic patients are significantly more likely to be addicted to nicotine.
- Trial name
- PSIAARP (NCT00495352)
- Testing
- Hihg-doseNRT, Low-dose NRT, bupropion
- Where
- Taiwan
- Volunteers
- 360 people
- Sponsor
- Yu-Li Hospital
Dementia
Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD
The aim of this study is to discontinue antipsychotics and antidepressants, and to study its effect on Behavioural- and Psychological Symptoms in Dementia (BPSD).
- Trial name
- NCT00433121
- Testing
- Risperidone, Olanzapine, Haloperidole
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- Sykehuset Innlandet HF
High Triglycerides, Hypercholesterolemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication.
- Conditions
- High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00833976
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Psychosis
Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis
The benefits and harms of antipsychotics are relatively well studied in adults. However, there is a lack of scientifically valid studies regarding the benefits and harms of antipsychotics in children and adolescents with…
- Trial name
- TEA (NCT01119014)
- Testing
- Aripiprazole, Quetiapine
- Where
- 9 sites in Denmark
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anne Katrine Pagsberg
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Death, Sudden, Cardiac, Arrythmia
Monitoring of Arrhythmias in Patients Treated With Antipsychotics
Antipsychotics may be associated to life-threatening arrhythmias and sudden cardiac death. This is the fist study to estimated the arrhythmic burden using long-term monitoring by implantable loop recorder in patients treated with…
- Conditions
- Death, Sudden, Cardiac, Arrythmia, Antipsychotics and Neuroleptics Toxicity
- Trial name
- MAPP (NCT04575103)
- Testing
- Antipsychotic
- Where
- 18 sites in Denmark
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Herlev and Gentofte Hospital
First Episode Psychosis
Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication
The purpose of this study is to determine whether Vitamin B12,B6 and Folic Acid are effective with antipsychotic medication in the treatment of First Episode Psychosis.The B-complex Vitamins' homocysteine lowering properties may…
- Trial name
- NCT00202280
- Testing
- Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg
- Where
- Australia
- Volunteers
- 120 people
- Sponsor
- Melbourne Health
Schizophrenia, Obesity
Metformin for Weight Loss in Schizophrenia
Study hypothesis is that patients on antipsychotics medication treated with metformin will show loss in weight and improved measures of glucose metabolism.
- Trial name
- NCT01177709
- Testing
- Metformin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
Alleviating the Metabolic Side Effects of Antipsychotic Medications
The use of antipsychotic medications has increased over the past decade. While more recently developed medications are improved with regards to extrapyramidal side effects, the use of atypical antipsychotics has been associated…
- Trial name
- NCT01567124
- Testing
- Moxonidine
- Where
- 4 sites in Australia
- Sponsor
- Baker Heart and Diabetes Institute
Obsessive-Compulsive Disorder
Treatment of Obsessive-Compulsive Disorder
The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics).
- Trial name
- NCT00000373
- Testing
- olanzapine + fluoxetine
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of Florida
Schizophrenia; Psychosis, Metabolic Syndrome
Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients
Fute (Flupentixol) combined with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) drugs has its clinical efficacy toward positive symptoms and might reduce the metabolic syndrome-related factors in patients.
- Conditions
- Schizophrenia; Psychosis, Metabolic Syndrome, Flupentixol, Antipsychotic Agents
- Trial name
- NCT04898270
- Testing
- Flupentixol, Multi-acting receptor-targeted antipsychotics (MARTAs)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Taichung Veterans General Hospital
Negative Symptoms of Schizophrenia
SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia
To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms…
- Trial name
- NSS (NCT01234298)
- Testing
- SPD489 Low-Dose, SPD489 High-Dose
- Sponsor
- Shire
Schizophrenia, Alzheimer's Disease
Side Effects of Newer Antipsychotics in Older Adults
This study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals.
- Conditions
- Schizophrenia, Alzheimer's Disease, Dementia
- Trial name
- NCT00245206
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Diabetes, Obesity
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
This program aims to help Veterans who take antipsychotic medications lose weight. The investigators use a program based on the American Diabetes Association's "Diabetes Prevention Program," and the investigators have modified it…
- Conditions
- Diabetes, Obesity, Weight Gain
- Trial name
- MAMAO (NCT00344500)
- Testing
- Behavioral Weight Loss Program
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder
The objective of the study is to evaluate the efficacy of raloxifene compared to placebo, as add-on to anti-psychotics in the treatment of post menopausal patients with schizophrenia.
- Trial name
- RAL-S-01 (NCT01280305)
- Testing
- raloxifene
- Where
- 13 sites in Israel, Romania
- Volunteers
- 200 people
- Sponsor
- Sheba Medical Center
Schizophrenia
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
- Trial name
- NCT00977522
- Testing
- PF-03463275
- Where
- 37 sites in United States
- Volunteers
- 207 people
- Sponsor
- Pfizer